Pharma and Biotech
Competitors: | Hemogenyx Pharmaceuticals |
Executive Director: | Daniel Gooding |
Independent Non-Executive Director: | Madeleine Kennedy |
Non-Executive Chairman: | Julian Gilbert |
Non-Executive Dir: |
Address: | C/O Arch Law Limited, Huckletree Bishopsgate, 8 Bishopsgate, London, United Kingdom, EC2N 4BQ |
Phone: | +44 (0)1223 627222 |
Website: | https://nuformix.com/ |
Sector: | Pharma and Biotech(LSE) |
ISIN: | GB00BYW79Y38 |
Currency | UK Pounds |
Share Price | 0.095p |
Change Today | 0.010p |
% Change | 11.76 % |
52 Week High | 0.20 |
52 Week Low | 0.048 |
Volume | 176,829,927 |
Shares Issued | 1,995.71m |
Market Cap | £1.90m |
Beta | 0.08 |
RiskGrade | 322 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:18 | 500,000 @ 0.100p |
16:18 | 500,000 @ 0.100p |
16:17 | 986,561 @ 0.100p |
16:16 | 1,982,587 @ 0.100p |
16:11 | 2,075,980 @ 0.093p |
You are here: research